02/06/2026
✨Our team is excited to have delivered the new Syfovre® (pegcetacoplan) treatment for geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).
Syfovre is the first approved therapy designed to slow the progression of GA by calming the immune response, helping to reduce further loss of retinal cells over time. While it does not restore lost vision, or stop the disease from worsening, it offers an important new option for patients seeking to preserve remaining vision for longer.
Patients need to be assessed for suitability and discuss with their eye doctor whether this treatment is appropriate.